about
von Willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia.Rectal metastases from lobular carcinoma of the breast: report of a case and literature review.Systematic review: hepatic fibrosis - regression with therapy.Treatment options beyond IFNα and NUCs for chronic HBV infection: expectations for tomorrow.von Willebrand factor antigen as a therapeutic target of portal hypertension in cirrhosis.Scintigraphic evaluation of intrapulmonary shunt in normoxemic cirrhotic patients and effects of terlipressin.Effects of terlipressin and somatostatin on liver and thorax blood volumes in patients with cirrhosis.Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia.Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values.Thrombosis and recanalization of straight sinus.Thrombin generation measured as thrombin-antithrombin complexes predicts clinical outcomes in patients with cirrhosis.Red signs and not severity of cirrhosis should determine non-selective β-blocker treatment in Child-Pugh C cirrhosis with small varices: increased risk of hepatorenal syndrome and death beyond 6 months of propranolol use.Pancreatitis potentially associated drugs as a risk factor for post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective cohort study.The true value of serum elastase-1 in endoscopic retrograde cholangiopancreatography (ERCP)Baseline cholesterol is associated with the response to antiviral therapy in chronic hepatitis CHigh von Willebrand factor antigen levels and procoagulant imbalance may be involved in both increasing severity of cirrhosis and portal vein thrombosisPropranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites
P50
Q33433053-C6FC2C02-B1CF-47CC-B342-D973BFAF5822Q34296778-6FF61F67-318E-4595-8178-9686D0ED416DQ37257759-DC9567F9-1995-4FE3-B229-EFAB6A7696A7Q38255840-7552084D-0524-4EF3-8F0A-1EB19C8AA1E2Q42781768-E09B7050-81C1-434F-986A-B874B96B220EQ42871776-98617172-AC68-4D5B-B6C8-99657B15C28AQ42926015-B92A820B-1DE0-4DA5-9037-A11CB6F63D33Q42942709-C32B9125-3313-442C-AF0F-79F5C6935A49Q44126764-94037069-16AC-474E-A7BD-32CB0B0F83F7Q48963078-B7B88018-2AF3-401F-8E11-90AC488685E9Q49118425-5DEC1848-D7B1-43ED-A75C-60619BC49D22Q50250447-B5DCBABE-8EF7-46D0-9F82-68A5788495E6Q50862292-DD7FB261-7330-41EF-9D5E-61D4934FF9FDQ74529393-BC2B6AB1-134E-41A5-A5AB-C17CC7C5CC61Q80323229-39FAAE81-0490-4669-AEC1-F4D1B46CDF31Q87764479-1CDC6267-A3A5-441A-BDB6-88C19C85F1F8Q89066426-D977F077-BAE2-41DA-9106-1F1D0CEAB630
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-0423-5312
@en
name
Gerasimos Baltayiannis
@ast
Gerasimos Baltayiannis
@en
Gerasimos Baltayiannis
@es
Gerasimos Baltayiannis
@nl
type
label
Gerasimos Baltayiannis
@ast
Gerasimos Baltayiannis
@en
Gerasimos Baltayiannis
@es
Gerasimos Baltayiannis
@nl
prefLabel
Gerasimos Baltayiannis
@ast
Gerasimos Baltayiannis
@en
Gerasimos Baltayiannis
@es
Gerasimos Baltayiannis
@nl
P106
P31
P496
0000-0002-0423-5312